CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC 50 of 520 nM
In Vivo
CCT369260 (compound 1, 15 mg/kg, po, single dose) significantly inhibits BCL6 in OCI-Ly1 DLBCL xenograft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: OCI-Ly1 DLBCL xenograft model (female SCID mice) . Dosage: 15 mg/kg. Administration: PO, single dose. Result: Decreased the levels of BCL6 in the tumor observed up to 10 h after administration. Animal Model: Female Balb/C mice . Dosage: 1 mg/kg iv and 5 mg/kg po (Pharmacokinetic Analysis). Administration: IV and PO Result: Demonstrated moderate clearance (CL 20 mL min −1 kg −1 ) with mean oral bioavailability of 54%.
IC50& Target:IC50: 520 nM (BCL6)
仕様
仕様と純度
10mM in DMSO
生化学的・生理学的メカニズム
CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC 50 of 520 nM.
保管条件
Store at -80°C
入荷
Dry ice packs + Cold packs
この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。
アクションタイプ
INHIBITOR
名前と識別子
分子量
508.99
詳細データ
証明書(CoA、COO、BSE/TSEと分析図)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
ソリューション計算機
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.